Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Bought by Paradice Investment Management LLC

Paradice Investment Management LLC raised its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 5.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 956,407 shares of the medical device company’s stock after buying an additional 52,966 shares during the period. Tandem Diabetes Care comprises about 6.8% of Paradice Investment Management LLC’s investment portfolio, making the stock its 4th biggest holding. Paradice Investment Management LLC owned 1.46% of Tandem Diabetes Care worth $34,450,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. Rice Hall James & Associates LLC raised its holdings in shares of Tandem Diabetes Care by 14.3% during the 4th quarter. Rice Hall James & Associates LLC now owns 105,482 shares of the medical device company’s stock valued at $3,799,000 after purchasing an additional 13,224 shares in the last quarter. Venturi Wealth Management LLC raised its holdings in shares of Tandem Diabetes Care by 5,955.9% during the 4th quarter. Venturi Wealth Management LLC now owns 2,059 shares of the medical device company’s stock valued at $74,000 after purchasing an additional 2,025 shares in the last quarter. Truist Financial Corp raised its holdings in shares of Tandem Diabetes Care by 2.1% during the 4th quarter. Truist Financial Corp now owns 119,561 shares of the medical device company’s stock valued at $4,307,000 after purchasing an additional 2,434 shares in the last quarter. AlphaCentric Advisors LLC bought a new position in shares of Tandem Diabetes Care during the 4th quarter valued at $292,000. Finally, Principal Financial Group Inc. raised its holdings in shares of Tandem Diabetes Care by 4.9% during the 4th quarter. Principal Financial Group Inc. now owns 388,347 shares of the medical device company’s stock valued at $13,988,000 after purchasing an additional 18,025 shares in the last quarter.

Tandem Diabetes Care Stock Up 2.6 %

NASDAQ TNDM opened at $33.47 on Tuesday. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. The company’s fifty day moving average is $35.63 and its two-hundred day moving average is $36.95. Tandem Diabetes Care, Inc. has a 52-week low of $22.03 and a 52-week high of $53.69.

Insiders Place Their Bets

In other news, Director Kim D. Blickenstaff sold 10,000 shares of Tandem Diabetes Care stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $30.00, for a total transaction of $300,000.00. Following the sale, the director now directly owns 195,190 shares in the company, valued at approximately $5,855,700. The trade was a 4.87 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. Sanford C. Bernstein assumed coverage on shares of Tandem Diabetes Care in a report on Wednesday, November 6th. They set an “outperform” rating and a $42.00 price target on the stock. Morgan Stanley upgraded shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 price target on the stock in a report on Monday, December 2nd. Barclays lifted their target price on shares of Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an “overweight” rating in a report on Friday, November 8th. Canaccord Genuity Group dropped their target price on shares of Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Finally, Robert W. Baird dropped their target price on shares of Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating on the stock in a report on Thursday, November 7th. Four analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $53.81.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.